Clinicopathological features of CD5-positive splenic marginal zone lymphoma.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-05-17 DOI:10.1136/jcp-2022-208603

Yunling Li, Guannan Wang, Enjie Liu, Dandan Zhang, Yanping Zhang, Xiangyu Jian, Wugan Zhao, Wencai Li

{"title":"Clinicopathological features of CD5-positive splenic marginal zone lymphoma.","authors":"Yunling Li, Guannan Wang, Enjie Liu, Dandan Zhang, Yanping Zhang, Xiangyu Jian, Wugan Zhao, Wencai Li","doi":"10.1136/jcp-2022-208603","DOIUrl":null,"url":null,"abstract":"Aims: To investigate the clinicopathological features, immunophenotypes and differential diagnosis of CD5-positive splenic marginal zone lymphoma (SMZL).Methods: We retrospectively analysed 16 CD5-positive cases of SMZL. Assess their clinicopathological features and survival outcomes to evaluate their similarities and differences with a control group of 25 CD5-negative cases of SMZL.Results: Compared with CD5-negative patients, CD5-positive SMZL tends to be more prone to B symptoms, peripheral lymphadenopathy and extranodal infiltration, high Ann Arbor stage, high International Prognostic Index scores, high serum lactic dehydrogenase and high rates of bone marrow involvement. The 5-year survival rate was significantly shorter than that of the CD5-negative group (52.1% and 81.8%, respectively).Conclusions: There are many similarities between CD5-positive SMZL and classical CD5-negative SMZL in clinical presentations, morphology and immunohistochemistry, but the former may have a more aggressive clinical course with a poorer prognosis.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"421-425"},"PeriodicalIF":4.6000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jcp-2022-208603","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To investigate the clinicopathological features, immunophenotypes and differential diagnosis of CD5-positive splenic marginal zone lymphoma (SMZL).

Methods: We retrospectively analysed 16 CD5-positive cases of SMZL. Assess their clinicopathological features and survival outcomes to evaluate their similarities and differences with a control group of 25 CD5-negative cases of SMZL.

Results: Compared with CD5-negative patients, CD5-positive SMZL tends to be more prone to B symptoms, peripheral lymphadenopathy and extranodal infiltration, high Ann Arbor stage, high International Prognostic Index scores, high serum lactic dehydrogenase and high rates of bone marrow involvement. The 5-year survival rate was significantly shorter than that of the CD5-negative group (52.1% and 81.8%, respectively).

Conclusions: There are many similarities between CD5-positive SMZL and classical CD5-negative SMZL in clinical presentations, morphology and immunohistochemistry, but the former may have a more aggressive clinical course with a poorer prognosis.

查看原文本刊更多论文

CD5阳性脾边缘区淋巴瘤的临床病理特征。

目的：研究CD5阳性脾边缘区淋巴瘤（SMZL）的临床病理特征、免疫表型和鉴别诊断：我们回顾性分析了 16 例 CD5 阳性的 SMZL 病例。方法：我们回顾性分析了16例CD5阳性脾边缘区淋巴瘤（SMZL）病例，评估他们的临床病理特征和生存结果，以评价他们与对照组25例CD5阴性SMZL病例的异同：结果：与CD5阴性患者相比，CD5阳性SMZL患者更容易出现B症状、外周淋巴结病和结外浸润、高Ann Arbor分期、高国际预后指数评分、高血清乳酸脱氢酶和高骨髓受累率。5年生存率明显低于CD5阴性组（分别为52.1%和81.8%）：结论：CD5阳性SMZL与经典的CD5阴性SMZL在临床表现、形态学和免疫组化方面有许多相似之处，但前者的临床病程可能更具侵袭性，预后较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464